Open AccessCurrent treatment of non-metastatic castration-refractory prostate cancer
Author(s) -
Tomáš Büchler
Publication year - 2021
Publication title -
klinická onkologie
Language(s) - English
Resource type - Journals
eISSN - 1802-5307
pISSN - 0862-495X
DOI - 10.48095/ccko2021185
Subject(s) - enzalutamide , medicine , prostate cancer , refractory (planetary science) , oncology , urology , prostate specific antigen , androgen receptor , cancer , physics , astrobiology
Non-metastatic castration-refractory prostate cancer (nmCRPC) is defined by increasing serum prostate specific antigen (PSA) levels despite androgen deprivation therapy in the absence of metastases on standard imaging methods including CT of the chest, abdomen and pelvis, and bone scan. Patients with nmCRPC and short PSA doubling time (PSAdt) are at high risk of developing early metastatic disease.